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ABSTRACT

A compound and method for using the compound to reduce
injury associated With ischemia and reperfusion of mamma
lian organs such as the heart. The compound may be
administered as part of a preconditioning strategy Which

reduces the extent of injury and improves organ function
folloWing cessation and restoration of blood ?oW. The

compound may be used in preparation for planned ischemia
or in a prophylactic manner in anticipation of further
ischemic events.

24 Claims, 4 Drawing Sheets
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PROTECTION AGAINST ISCHEMIA AND
REPERFUSION INJURY

methods and agents to provide protection against myocardial
ischemia and to avoid post ischemic dysfunction are needed.

FIELD OF THE INVENTION

SUMMARY OF THE INVENTION

The invention relates to compounds protective against
ischemia and reperfusion injury, particularly in the

The invention is directed to an agent and a method of

using the agent to reduce the injury associated With ischemia
and reperfusion of organs such as the heart. The compound

myocardium, and their use.
BACKGROUND

Tissues deprived of blood and oxygen undergo ischemic

10

NO:1, particularly prior to an ischemic event, reduces tissue

necrosis or infarction With possible irreversible organ dam
age. In some circumstances, hoWever, such as during cardiac

surgery, it is desirable to interrupt the normal myocardial

contractions (cardioplegia) and actually induce ischemia.
Such elective or obligatory ischemia occurs in the presence

15

of safeguards such as cardioplegia-induced cardiac arrest

and hypothermia. While these safeguards provide consider
able myocardial protection, alteration of myocardial ener
getics (stunning) and poor postoperative ventricular function
still remain signi?cant problems.

1—20 mg/kg of body Weight.
25

The invention is also directed to a method to prevent
damage to an isolated organ, for example, a heart for

transplant. The isolated organ is exposed to a preservative
solution containing an effective amount of compound-D
SEQ ID NO:1. The concentration of compound-D SEQ ID
NO:1 in the preservative solution for a heart is about 100

restores oxygen and reverses ischemia, repletion of high
energy nucleotides such as adenosine triphosphate (ATP)
and reversal of ischemic membrane damage is sloW, and
contractile function may be profoundly depressed for a long
period. Just minutes of ischemia causes loss of myocardial
systolic Wall thickening for hours. Longer periods of revers

pM.
The invention is additionally directed to a method for

35

con?rm that, despite restoration of myocardial How and a

quick recovery of myocardial oxygen consumption (MVO2)

reducing effects of an ischemic episode in a mammal by
administering an effective concentration of compound-D
SEQ ID NO:1 in a pharmaceutically acceptable carrier.
Administration is prior to or substantially concurrently With
the onset of ischemia, or one hour post cerebral ischemia.
The invention is further directed to a composition that

folloWing ischemia, there is only very sloW recovery of
myocardial contractile function. The problems are exacer
bated in high risk patients, such as those With poor preop
erative ventricular function, recent myocardial infarction or
left ventricular hypertrophy. These same problems also
occur during organ storage for cardiac transplant, under

protects a mammalian organ from injury. The composition
contains compound-D SEQ ID NO:1. Compound-D may be
naturally occurring or may be synthesiZed.

Which there are time constraints due to the limits of myo

cardial preservation.

An effective concentration of compound-D SEQ ID NO:1 is
administered to the mammal in a pharmaceutically accept
able formulation prior to the onset of ischemia, for example,
24 hours prior to ischemia. In other embodiments,
concurrent With the onset of ischemia, during an ischemic
episode, or post-ischemia. The formulation may be admin
istered parenterally at a concentration in the range of about

damage that resolves only sloWly. Although reperfusion

ible ischemia may depress contractility for days. Studies

necrosis and preserves organ function.
In one embodiment, a method of protecting against
ischemia and reperfusion injury in a mammal is disclosed.

compound-D SEQ ID NO:1 is administered substantially

Once the How of blood and oxygen is restored to the organ
or tissue (reperfusion), the organ does not immediately

return to the normal preischemic state. Reperfused postis
chemic non-necrotic myocardium is poorly contractile and
has reduced concentrations of high energy nucleotides,
depressed subcellular organelle function and membrane

is Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp
Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO:1, hereinafter
compound-D. Administration of compound-D SEQ ID

45

Postischemic dysfunction may be due to a variety of
factors. Oxygen free radicals may play a role, as generation
of free radicals in stunned myocardium has been demon
strated and free radical scavengers have been shoWn to

The invention is also directed to an organ preservative
solution that contains compound-D at a concentration effec
tive to protect the organ, such as a heart, from ischemic

injury.
These and other advantages of the invention Will be

apparent in light of the folloWing draWings and detailed

description.

attenuate contractile dysfunction. Impaired intracellular cal

BRIEF DESCRIPTION OF THE DRAWINGS

cium handling and calcium overload during early reperfu
sion may contribute to postischemic dysfunction; While
calcium infusions enhance contractility in both normal and

FIG. 1 is a histogram shoWing myocardial infarction siZe
in control and treated animals.

postischemic myocardium, ischemia as short as a feW min

utes produces an impairment in sarcoplasmic reticulum
calcium transport and a shift of the calcium ATPase activity.
Postischemic myocardium is also associated With reduced

FIG. 2 is a histogram shoWing post-ischemic release of
55

FIG. 3 is a histogram shoWing post-ischemic release of
troponin I in control and treated animals.
FIG. 4 is a graph shoWing end diastolic pressure in the left
ventricle of control and treated animals.
FIG. 5 is a graph shoWing functional recovery in control
and treated animals.
FIG. 6 is a graph shoWing coronary flow in control and
treated animals.

concentrations of myocardial high-energy phosphates and
adenine nucleotides, as obligatory reduction in myocardial
ATP content during ischemia occurs as myocytes utiliZe ATP

for maintenance of cellular integrity. Since ATP is essential

for myocardial contraction and relaxation, ATP depletion
may have detrimental effects upon postischemic myocardial
functional recovery.

The high volume of cardiac-related surgeries, both elec
tive and emergency procedures and including cardiac
transplants, lead to the above-described problems. Thus,

creatine kinase in control and treated animals.

65

FIG. 7 is a histogram shoWing the effect of naltrexone on

infarct siZe in animals pretreated With compound-D SEQ ID
NO:1.

US 6,316,411 B1
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FIG. 8 is a histogram showing the effect of glibenclamide

mm Hg by regulating coronary ?oW. All hearts Were paced

on vas deferens contractility in animals treated With 1,000

at 5.5 HZ (300 beats per minute, bpm) except during

nM compound-D SEQ ID NO: 1.
FIG. 9 is a histogram shoWing the effect of glibenclamide

ischemia. A saline-?lled balloon Was inserted in the left

ventricle to measure developed pressure (DP) and end
diastolic pressure (EDP) in mm Hg. After 15 min

on vas deferens contractility in animals treated With 2,000

equilibration, both groups Were subjected to 20 min Zero

nM compound-D SEQ ID NO:1.

?oW global ischemia, and then Were reperfused for 120 min.
DETAILED DESCRIPTION

Left ventricles Were isolated and divided into three seg

ments along their short axis, stained With triphenyltetraZo

The invention is directed to a compound that has a

salutary effect on cardiac function folloWing ischemia, and
methods of using the compound. The compound may be

10

lium chloride, and stored in formalin. Infarct siZe Was
measured on digitiZed images and expressed as a per centage

of myocardium. Data Were expressed as mean plus or minus
standard error of the mean (:SEM) and Were analyZe using
a paired Student’s t-Test. Con?dence limits Were established
15 at 95%.
The results are shoWn in FIG. 1, Which is a histogram of
preservative solution for an isolated organ, such as a heart or

administered directly to an individual, and is particularly
effective When administered 24 h prior to the onset of
ischemia. This may occur, for example, prior to scheduled
cardiac surgery. The compound may also be included in a

the infarct siZe in hearts from both animals receiving only
saline (control, solid bar) and in animals treated With

liver being maintained viable for transplant.
The compound is a peptide having the sequence Tyr-D

compound-D SEQ ID NO:1 at 2.0 mg/kg (treated, open bar)

Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-lie-Gly-Asp-Phe-Phe

24 h prior to 20 min ischemia and 120 min reperfusion.
Pretreatment of animals With compound-D SEQ ID NO:1

His-Ser-IIe-NH2 SEQ ID NO: 1, hereinafter referred to
compound-D. The peptide may be produced by a number of
methods, such as using an automated peptide synthesiZer,
through recombinant molecular techniques, or isolated from

signi?cantly decreased the percent of infarct siZe (p<0.05).
Control rats had a mean infarct siZe of 27:5%, While rats

pretreated With compound-D had a reduced mean infarct
siZe of 12:3%.

a naturally occurring source, as is knoWn to one skilled in the

art. Compound-D SEQ ID NO:1 has a molecular Weight of
1,902 daltons. Compound-D SEQ ID NO:1 is insoluble in
Water or saline, but may be solubiliZed by adding 100 pM of

Compound-D SEQ ID NO:1 pretreatment also signi?
cantly decreased total creatine kinase (CK) and the cardiac
form of troponin I (cTn-1) values folloWing 20 min

a solution comprised of ethanol, propylene glycol, and 1 N

ischemia, as shoWn in FIGS. 2 and 3, respectively. CK is an
enZyme that is normally found in muscles such as the heart

NaOH in a 1:111 ratio, With sterile physiological saline then
used to obtain the appropriate concentration. The initial
alkaline pH is adjusted to 7.4 With 1 N HCI.
Compound-D SEQ ID NO:1 that has been solubiliZed

(that is, in myocytes), but is released during severe muscle
trauma such as occurs in a myocardial infarction. Thus,

may be administered by parenteral means, for example, by
intravenous injection. In one embodiment, administration of
compound-D SEQ ID NO:1 is at the time of induced

35

indicates myocardial damage.

ischemia, but may also be added during or even after an
ischemic event. For administration into a mammal, a dose of

FIG. 2 is a histogram shoWing CK released during rep
erfusion of isolated rat hearts after 20 min ischemia in rats

about 1—20 milligrams per kilogram (mg/kg) is useful. For
administration into a tissue or organ preservation solution, a

measurement of CK is an indicator of the degree of muscle
damage or trauma. Similarly, cTn-l is a protein associated
speci?cally With cardiac muscle, and an increase in cTn-1

40

treated 24 h prior to ischemia With 2.0 mg/kg compound-D
SEQ ID NO:1. The solid bars represent control animals

concentration of about 100 pM is useful.
Compound-D SEQ ID NO:1 may be administered directly

(n=6) and the open bars represent treated animals (n=6).
FIG. 3 is a histogram shoWing cTn-l released during rep

into a mammal, either alone or in combination With other
substances. Alternatively, it may be added as a component of
a solution used to maintain the viability of isolated organs,
such as an additive to cardioplegia and other organ preser

erfusion of isolated rat hearts after 20 min ischemia in rats
45

(n=6) and the open bars represent treated animals (n=6). At
each time point during reperfusion Where samples Were
collected for CK and cTn-1 analysis (1, 1 5, 30, 60, 90 and

vation solutions. In one embodiment, compound-D SEQ ID
NO:1 is coadministered as an adjuvant With other com

pounds or strategies that are designed to protect organs from
ischemia. As an example, compound-D SEQ ID NO:1 may
be administered With agents that affect nitric oxide (NO)

50

synthase, such as arginine hydrochloride. Arginine hydro
chloride is knoWn to prevent the decline in cardiac function

folloWing an ischemic episode.
The folloWing description demonstrates use and ef?cacy
of compound-D SEQ ID NO:1 in a variety of systems.

55

in the same manner With an equal volume of 0.9% NaCI.

After 24 h, the hearts from both treated and control animals
Were excised and perfused in a modi?ed Langendorff per
Henseleit buffer as the perfusate, as knoWn to one skilled in

the art. Coronary perfusion pressure Was maintained at 70

that pretreatment With compound-D SEQ ID NO:1
decreased the damage to the myocardium, as compared to
animals that did not receive compound-D SEQ ID NO:1.
Compound-D SEQ ID NO:1 pretreatment also resulted in
improved postischemic ventricular function. FIG. 4 is a
min ischemia in rats treated 24 h prior to ischemia With 2.0

60

(number of animals (n)=6). Control rats (n=6) Were injected

fusion apparatus at 37° C. using oxygenated Krebs

120 min reperfusion), CK levels in control rats Were higher
than CK levels in treated rats, and Tn—1 levels in control rats
Were higher than Tn—1 levels in treated rats. This indicated

graph of end diastolic pressure (EDP) in mm/Hg in the left
ventricle during reperfusion of isolated rat hearts after 20

PERFUSED HEART

Compound-D SEQ ID NO:1, at a dose of 2 mg/kg and
solubiliZed as described above, Was administered by tail
vein injection into rats Weighing betWeen about 350—400 g

treated 24 h prior to ischemia With 2.0 mg/kg compound-D
SEQ ID NO:1. The solid bars represent control animals

65

mg/kg compound-D SEQ ID NO:1. Open squares are from
treated animals, and solid circles are from control animals.
FIG. 5 is a graph shoWing percent of functional recovery
during reperfusion of isolated rat hearts after 20 min
ischemia in rats treated 24 h prior to ischemia With 2.0
mg/kg compound-D SEQ ID NO:1. Open squares are from
treated animals, and solid circles are from control animals.
Differences in recovery of developed pressure (DP) of

US 6,316,411 B1
5
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compound-D SEQ ID NO:1 treated hearts remained statis
tically signi?cant to 90 min following initiation of
reperfusion, as shoWn in FIG. 4, and in end diastolic
pressure to 20 min following initiation of reperfusion, as
shoWn in FIG. 5. Left ventricular functional recovery (%

FIG. 9 shoWs the effect of administration of 2000 nM

compound-D alone (open bars) versus 2000 nM
compound-D SEQ ID NO:1 With 6000 nM glibenclamide

(hatched bar) on contractility of m.v.d. (n=2).
These results demonstrate that the effect of compound-D

recovery of baseline preischemic developed pressure during
reperfusion) Was markedly improved in treated animals
(open squares) compared to control animals (solid circles) to

SEQ ID NO:1 requires opening and/or activation of KATP
channels since glibenclamide, a potassium channel blocker,

(solid circles) and compound-D SEQ ID NO:1 treated

effectively blocked the smooth muscle inhibition of contrac
tion induced by compound-D SEQ ID NO:1 in the m.v.d.
assay. The possibility therefore eXists that administration of
compound-D SEQ ID NO:1 and interventions directly tar

animals (open squares).

geted at opening KATP channels by drugs such as nicorandil

90 min of reperfusion. As shoWn in FIG. 6, coronary How
Was not signi?cantly different betWeen control animals

These results shoW that in a normoXic, isolated perfused
rat heart preparation, administration of compound-D can
confer cardioprotection When administered 24 h prior to
planned ischemia. The salutary effects on the post-ischemic

10

or diaZoXide, or anesthetics such as iso?urane, could be

effective approaches for pharmacologically duplicating both
15

myocardium include reduced infarct siZe, decreased release
of both creatine kinase and cardiospeci?c troponin 1, and

improved ventricular performance.
FIG. 7 shoWs the effect of naltreXone, a universal opioid
antagonist, on infarct siZe. Groups of rats Were pretreated 24

short term and long term (second WindoW) ischemic pre

conditioning. Thus, preinfusions of compound-D SEQ ID

20

NO:1 may provide extended protection to the ischemic
myocardium in a variety of clinical scenarios.
Compound-D, SEQ ID NO:1 has also been shoWn to be
effective in reducing ischemic effects When administered 1
h after an episode of induced cerebral ischemia. A solution

h prior to ischemia With either compound-D SEQ ID NO:1

of 100 ML of either vehicle alone (control) or compound-D

at a dose of 2.0 mg/kg (n=6), naltreXone at a dose of 3 mg/kg
(n=6), or a combination of compound-D SEQ ID NO:1 at a
dose of 2.0 mg/kg and naltreXone at a dose of 3 mg/kg (n=6).
Control rats (n=6) received vehicle (1 :1 :1 solution of 1 N

(treated) at a concentration of 1 mg/ml Was administered
either 1 h before cerebral ischemia or 1 h after cerebral
25

NaOHzpropyleneglycol:ethanol, readjusted to 7.4 With HCI)
only. After 24 h pretreatment, isolated rat hearts Were
subjected to 20 min ischemia folloWed by 120 min reper
fusion.
As shoWn in FIG. 7, these data indicate that naltreXone
administered in combination With compound-D SEQ ID
N011 did not block the cardioprotective effects of
compound-D SEQ ID NO:1. In fact, the data support a
synergistic cardioprotective effect from administration of a
combination of compound-D SEQ ID NO:1 and naltreXone.
Administration of compound-D SEQ ID NO:1 reduced
infarct siZe from about 27% in the control group (solid bar)
to about 13% in the compound-D SEQ ID NO:1 treated

group (open bar) (p=0.05). The combined preischemic
administration of compound-D SEQ ID NO:1 and naltreX
one (doWnWard hatched bar) red to about 10% When com
pared to the control group (p=0.05). Additionally, these data
demonstrate that compound-D SEQ ID NO:1 does not
operate via delta opioid receptors, since naltreXone, an

30

ischemia (n=6 in each group). In animals receiving
compound-D before ischemia, there Were no signi?cant
differences in infarct volume (control 91:10 mm3 versus
treated 89:11 mm3) or neurological score (control group
1.93:0.29 versus treated group 1.95:0.33). HoWever, When
compound-D Was administered 1 h post ischemia, there
Were signi?cant difference in both the infarct volume
(control group 90:13 mm3 versus treated group 5619 mm3)
and the neurological score (control group 1.91:0.27 versus

treated group 1421028) in rats receiving compound-D SEQ
35 ID NO:1 versus the control group. The mean arterial blood

pressure, P02, pCO2, pH and cerebral blood ?oW shoWed no
signi?cant differences in control versus treated groups When
compound-D SEQ ID NO:1 Was administered either pre or

post-cerebral ischemia (data not shoWn). These results sug
40

gest a therapeutic role for compound-D SEQ ID NO:1 in
mitigating the effects of a cerebral ischemic episode that is
in progress or that has occurred.
In summary, a compound that is administered to a mam

45

mal to reduce the injury associated With ischemia and
reperfusion of organs such as the heart is disclosed. The

opioid receptor antagonist, did not prevent compound-D
SEQ ID NO:1 activity in reducing infarct siZe (about 14.5%

compound is Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile

versus about 13%, respectively).

istration prior to an ischemic event reduces tissue necrosis

Mouse Vas Deferens
UtiliZing a mouse vas deferens (m.v.d.) assay,

Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO:1. Admin
50

compound-D SEQ ID NO: 1, it Was demonstrated that opioid

be administered in a time frame from 24 h up to 15 min prior
to planned ischemia, or even during an ischemic period.
It should be understood that the embodiments of the

receptor binding requires activation and/or opening of KATP
channels. Glibenclamide, a KATP channel blocker, blocked

present invention shoWn and described in the speci?cation

the inhibition of contraction of mouse vas deferens induced

by compound-D SEQ ID NO:1. With reference to FIG. 8, the
effect of administration of 1000 nM compound-D SEQ ID
NO:1 alone (open bar) versus 1000 nM compound-D SEQ
ID NO:1 With 6000 nM glibenclamide (hatched bar) on
contractility of mouse vas deferens (m.v.d.) (n=6) is shoWn.

55

Glibenclamide restored m.v.d. contractions Which

60

compound-D SEQ ID NO:1 had suppressed. FIG. 8 shoWs
that 1000 nM compound-D SEQ ID NO:1 suppressed con
tractility to above 100%. FIG. 8 also shoWs that differences
betWeen control contractions and 1000 nM compound-D

and preserves organ function, as measured by standard
physiological indices of organ function. The compound may

are only preferred embodiments of the inventors Who are
skilled in the art and thus are not limiting in any Way. For
example, compound-D SEQ ID NO:1 may be used as a

protective agent for organs other than the heart. Organs
isolated for transplant such as kidney, liver, lung, cornea, etc.
may have enhanced viability after eXposure to compound-D
SEQ ID NO:1. Similarly, compound-D SEQ ID NO:1 may

be administered to individuals in Which ischemia to organs
other than the heart has occurred or Will occur. Therefore
various changes, modi?cations or alterations to these
SEQ ID NO: 1, as Well as control versus 6000 nM 65 embodiments may be made or resorted to Without departing

glibenclamide, and 1000 nM compound-D SEQ ID NO:1
versus 6000 nM glibenclamide are statistically signi?cant.

from the spirit of the invention and the scope of the

folloWing claims.
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SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

<210>
<2ll>
<2 12>
<213>
<220>

1

SEQ ID NO 1
LENGTH: 17
TYPE: PRT
ORGANISM: XYZ
FEATURE:

<221> NAME/KEY: PEPTIDE
<222>

LOCATION:

(0) . . . (0)

<221> NAME/KEY: MODIREs
<222> LOCATION:

( 1) . . . (0)
<223> OTHER INFORMATION: Xaa = D-Leu

<400> SEQUENCE: 1

Tyr Xaa Phe Ala Asp Val Ala Ser Thr Ile Gly Asp Phe Phe His Ser
1

5

l0

15

Ile

What is claimed is:

1. Acomposition comprising compound-D SEQ ID NO:1.
2. The composition of claim 1 wherein compound-D SEQ

25

14. The method of claim 6 Wherein the formulation
further includes a compound having an anti-ischemic effect.
15. The method of claim 14 Wherein the compound affects

ID NO:1 is obtained by in vitro synthesis.
3. The composition of claim 1 Wherein compound-D SEQ

nitric oXide synthase.

ID NO:1 is isolated from a natural source.

arginine hydrochloride.

4. A solution to preserve viability of an isolated organ
comprising compound-D SEQ ID NO:1 at a concentration
effective to protect the organ from ischemic injury.
5. The solution of claim 3 Wherein the organ is selected

NO:1 is administered at a concentration in the range of about

from the group consisting of heart, liver, kidney, cornea,
lung, and combinations thereof.
6. A method of protecting against ischemia and reperfu

16. The method of claim 15 Wherein the compound is

17. The method of claim 6 Wherein compound-D SEQ ID

1—20 mg/kg of body Weight.
35

sion injury in a mammal comprising administering an effec
tive amount of compound-D SEQ ID NO:1 to the mammal
in a pharmaceutically acceptable formulation.
7. The method of claim 6 Wherein administration is prior

from the group consisting of heart, liver, kidney, cornea,
lung and combinations thereof.
20. The method of claim 18 Wherein compound-D SEQ
ID NO:1 is at a concentration of about 100 NM in the
solution.
21. A method for reducing effects of ischemia in a
mammal comprising administering an effective amount of

to onset of ischemia.

8. The method of claim 7 Wherein administration is about
24 hours prior to onset of ischemia.
9. The method of claim 6 Wherein compound-D SEQ ID
NO:1 is administered as a solution.

10. The method of claim 6 Wherein compound-D SEQ ID
NO:1 is administered parenterally.
11. The method of claim 6 Wherein compound-D SEQ ID
NO: 1 is administered at a concentration in the range of about

2 mg/kg of body Weight of the mammal.
12. The method of claim 6 Wherein compound-D SEQ ID
NO:1 is administered to protect against myocardial
ischemia.
13. The method of claim 2 Wherein said myocardial
ischemia occur during surgery.

18. A method to preserve at least one isolated organ
comprising eXposing the organ to a solution comprising a
preservative and an effective amount of compound-D.
19. The method of claim 18 Wherein the organ is selected
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compound-D SEQ ID NO:1 in a pharmaceutically accept
able carrier to the mammal.

22. The method of claim 21 Wherein compound-D SEQ
ID NO:1 is administered prior to ischemia.
23. The method of claim 21 Wherein compound-D SEQ

ID NO:1 is administered substantially concurrently With
onset of ischemia.

24. The method of claim 21 Wherein compound-D SEQ
ID NO: 1 is administered after one hour of cerebral ischemia.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.
DATED

: 6,316,411 B1
: November 13, 2001

Page 1 of 2

INVENTOR(S) : Oeltgen et al.
It is certified that error appears in the above-identi?ed patent and that said Letters Patent is
hereby corrected as shown below:

Column 3

Line 19, “Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-lie-Gly-Asp-Phe-Phe-His-Ser-IIe
NH2” should be -- Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His
Ser-Ile-NH2 -

Line 31, change “HCI” to -- HCl Line 62, change “NaCI” to -- NaCl -

Column 4
Line 11, change “per centage” to -- percentage Line 14, change “analyze” to -- analyzed -

Column 5
Line 18, change “troponin 1” to -- troponin l Line 27, change “HCI” to -- HCl -

Line 42, change “red to about” to -- reduced infarct size to about -

Column 6
Line 38, change “pre or post-cerebral” to -- pre- or post-cerebral -

Column 7
Line 33, change “The solution of claim 3 wherein” to -- The solution of claim 4
wherein -

Line 49, change “concentration in the range of about 2 mg/kg of body weight” to
-- concentration of 2 mg/kg of body weight -

Line 54, change “The method of claim 2 wherein said myocardial ischemia occur during
surgery.” to -- The method of claim 12 wherein said myocardial ischemia occurs during
surgery. -

Column 8
Line 31, change “range of about 1-20 mg/kg of body weight.” to -- range of 1-20 mg/kg
of body weight of the mammal. Line 35, change “effective amount of compound-D.” to -- effective amount of
compound-D SEQ ID NO:1. -

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.
DATED

: 6,316,411 B1
: November 13, 2001

Page 2 of 2

INVENTOR(S) : Oeltgen et al.
It is certified that error appears in the above-identi?ed patent and that said Letters Patent is
hereby corrected as shown below:

Column 8 cont’d
Line 41, change concentration of about 100 ,uM” to -- concentration of 100 ,uM -

Line 50, change “administered substantially concurrently With onset” to -- administered
with onset -

Signed and Sealed this

Tenth Day of September, 2002
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JAMES E. ROGAN

Arresting O?’icer

Direcror ofrhe United States Patent and Trademark O?‘ice

